The portable ATUSA™ System reportedly provides 3D ultrasound visualization of the entire breast volume in two minutes.
A new modality that may redefine the efficiency of breast imaging has received 510(k) clearance from the Food and Drug Administration (FDA). The new ATUSA™ System, a portable whole breast ultrasound device, can provide 3D imaging in two minutes, according to iSono Health, the manufacturer of the device.
Featuring intuitive software designed to integrate with machine learning models, the ATUSA system provides efficient automated scans of breast volume and analysis. Emphasizing patient comfort, the ultrasound device also offers a compact portability with a unique wearable accessory.
“A portable and automated whole breast ultrasound augmented with machine learning would be the most practical technology to reduce breast cancer mortality globally, specifically in countries with limited resources. In developed countries, ultrasound has proven effective as an adjunct to mammography to improve breast cancer diagnosis in women with dense breasts,” noted Mohammad Eghtedari, M.D., Ph.D., a breast radiologist and assistant professor at the University of California-San Diego. “I believe iSono Health’s automated and portable technology will improve access to breast care for women worldwide and empower physicians with insightful data to make more informed clinical decisions.
The ATUSA system also facilitates consistent, reproducible accuracy, regardless of the experience level of the physician, Maryam Ziaei, Ph.D., the co-founder and CEO of iSonoHealth
“Clinicians and women worldwide need high quality breast imaging that is accessible and efficient at scale without the need for highly skilled operators,” emphasized Maryam Ziaei, Ph.D, the co-founder and CEO of iSonoHealth. “The portable and automated ATUSA system stands alone in comparison to other ultrasound offerings in promising to address that need.”
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
FDA Clears Controlled Contrast Delivery Method for Ultrasound Imaging of Fallopian Tubes
September 9th 2024Facilitating natural contrast delivery through an intrauterine catheter, FemChec can be utilized for ultrasound assessment of fallopian tubes and may provide diagnostic confirmation for an emerging non-surgical option for permanent birth control.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
FDA Clears Emerging Cardiovascular Point-of-Care Ultrasound Platform
August 22nd 2024Combining four CAD modules for valvular pathologies with a variety of automated measurements, the AI-enabled AISAP Cardio ultrasound system reportedly facilitates up to a 90 percent accuracy rate in detecting common cardiac conditions.
Predicting DCIS Upgrade to Invasive Breast Cancer: Can Contrast-Enhanced Ultrasound Have an Impact?
August 21st 2024Adding two key findings from contrast-enhanced ultrasound to a predictive model of mammography, conventional ultrasound and clinicopathological findings led to a 86.1 percent AUROC for predicting the upgrading of ductal carcinoma in situ to invasive breast cancer, according to new research.